Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its chief executive officer said in an interview.Lilly’s drug, Kisunla, launched ...

Two new groundbreaking drugs could slow the memory impairment, thinking skills and overall brain decline — and both are ...

U.S. pharmaceutical company Eli Lilly is expected to disclose the top-line results (key findings from phase 3 clinical trials ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...

The Food and Drug Administration announced Tuesday the approval of a new Alzheimer’s drug from Eli Lilly, which has demonstrated moderately slow cognitive and memory decline in patients with the ...

Eli Lilly's potential Alzheimer's disease treatment failed to slow mental decline in two late-stage studies, but combined data from both trials showed promising results in patients with ...

A highly anticipated Alzheimer’s medication from Eli Lilly gained the support of a federal advisory panel Monday, paving the way for it to become the second drug of its kind authorized in the United ...

FILE PHOTO: A scientist looks at hypometabolic and hypoperfusion patterns at the single-subject level from a patient suffering from Alzheimer's disease at the Memory Centre at the Department of ...

Investing.com -- Biogen Inc. ’s new at-home Alzheimer’s drug will provide an advantage over Eli Lilly Co. ’s competing ...